Gerold Mönnig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gerold Mönnig has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Kristina Wasmer
Division of Clinical and Experimental Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Germany
3 shared publications - Lars Eckardt
University Hospital, Münster, Germany
3 shared publications Günter Breithardt
2 shared publications- Alexis Vrachimis
Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
1 shared publication Anika Ohlenburger
1 shared publication- Christian Pott
Division of Electrophysiology, Department of Cardiovascular Medicine, University Hospital Münster, Münster, Germany
1 shared publication
Latest Publications
- 24 February 2016
- Published by Elsevier in Heart Rhythm
- Vol. 13 (8) , 1596-1601
Lower rate of left atrial tachycardia after pulmonary vein isolation with PVAC versus irrigated-tip circumferential antral ablation
- 24 February 2016
- Published by Elsevier in Heart Rhythm
- Vol. 13 (8) , 1596-1601
Lower rate of left atrial tachycardia after pulmonary vein isolation with PVAC versus irrigated-tip circumferential antral ablation
- 29 July 2014
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 25 (4) , 236-240
Multielectrode Pulmonary Vein Ablation Catheter (PVAC®)
Electrical isolation of pulmonary veins is the cornerstone of catheter ablation for patients with symptomatic atrial fibrillation. However, uncertainty surrounds the choice of energy source in pulmonary vein isolation (PVI). Various alternative techniques such as the Pulmonary Vein Ablation Catheter (PVAC®, Medtronic Inc., Minneapolis, MN, USA) have been developed to facilitate PVI. This over-the-wire multielectrode catheter is delivering duty-cycled bipolar and unipolar radiofrequency (RF) energy at relatively low power. PVI with this “one-shot” PVACatheter can shorten the procedure duration and lower fluoroscopy time compared to irrigated RF. It enables mapping and ablation with the same array, but fails to show signals during RF energy delivery. The effectiveness of PVAC is comparable to other technologies in randomized studies. The overall complication rate of PVAC PVI is comparable to irrigated RF and possibly slightly higher for cryoballoon PVI. Special attention has to be paid to an effective anticoagulation throughout the ablation procedure, avoidance of embolic events and pulmonary venous stenosis. The novel catheter design of the PVAC Gold® array may improve safety by reducing embolic events through avoidance of electrode 1-to-10 interaction and by better tissue contact due to the 20° forward tilt. Although clinical data with this new array are lacking so far, the PVAC system has been shown to be a promising tool for PVI. However, prospective studies especially with the novel array are required to determine its true role for catheter ablation of atrial fibrillation in the future. Die elektrische Isolation der Pulmonalvenen (PVI) ist nach wie vor ein entscheidender Endpunkt der interventionellen Behandlung von Vorhofflimmern (AF). Daher sind einige alternative „single-shot“ Kathetertechnologien wie der „Pulmonary Vein Ablation Catheter“ (PVAC®, Medtronic Inc., Minneapolis, MN, USA) entwickelt worden. Dieser Multielektrodenkatheter wird über einen Draht eingeführt und gibt eine phasenverschobene bipolare wie unipolare relativ niedrige Radiofrequenzenergie (RF) ab. Sowohl die Untersuchungsdauer als auch die Durchleuchtungszeit sind für dieses System kürzer verglichen mit der gekühlten RF-Energie. Dies kann durch den Vorteil des gleichzeitigen Mappings und Abladierens bedingt sein, wobei die Signale während der Impulsabgabe artefaktbedingt nicht beurteilbar sind. Auch die Effektivität des PVAC-Katheters ist in randomisierten Studien vergleichbar mit anderen Technologien. Komplikationen treten bei PVAC-Therapie etwa gleich häufig auf wie bei gekühlter RF-Ablation und sind bei Kryoballonablation sogar geringfügig höher. Dennoch sollte dem Auftreten von Thrombembolien und Pulmonalvenenstenosen sowie einer effektiven Antikoagulation besonderes Augenmerk bei PVAC-PVIs gewidmet werden. Das neue Design des PVAC Gold® Katheters wird möglicherweise die Sicherheit verbessern, indem das Thrombembolierisiko durch die fehlende Interaktion der Elektroden 1 und 10 und durch einen besseren Gewebekontakt durch eine 20° Vorwärtsneigung der Katheterspirale verringert wird. Diesbezüglich liegen bislang allerdings noch keine klinischen Daten vor. Zusammenfassend stellt das PVAC-System eine vielversprechende Alternative zur PVI dar. Prospektive Studien mit dem neuen Katheterdesign sind erforderlich, um den zukünftigen Stellenwert des Verfahrens beurteilen zu können.
- 29 July 2014
- Published by Springer Nature in Herzschrittmachertherapie + Elektrophysiologie
- Vol. 25 (4) , 236-240
Multielectrode Pulmonary Vein Ablation Catheter (PVAC®)
Electrical isolation of pulmonary veins is the cornerstone of catheter ablation for patients with symptomatic atrial fibrillation. However, uncertainty surrounds the choice of energy source in pulmonary vein isolation (PVI). Various alternative techniques such as the Pulmonary Vein Ablation Catheter (PVAC®, Medtronic Inc., Minneapolis, MN, USA) have been developed to facilitate PVI. This over-the-wire multielectrode catheter is delivering duty-cycled bipolar and unipolar radiofrequency (RF) energy at relatively low power. PVI with this “one-shot” PVACatheter can shorten the procedure duration and lower fluoroscopy time compared to irrigated RF. It enables mapping and ablation with the same array, but fails to show signals during RF energy delivery. The effectiveness of PVAC is comparable to other technologies in randomized studies. The overall complication rate of PVAC PVI is comparable to irrigated RF and possibly slightly higher for cryoballoon PVI. Special attention has to be paid to an effective anticoagulation throughout the ablation procedure, avoidance of embolic events and pulmonary venous stenosis. The novel catheter design of the PVAC Gold® array may improve safety by reducing embolic events through avoidance of electrode 1-to-10 interaction and by better tissue contact due to the 20° forward tilt. Although clinical data with this new array are lacking so far, the PVAC system has been shown to be a promising tool for PVI. However, prospective studies especially with the novel array are required to determine its true role for catheter ablation of atrial fibrillation in the future. Die elektrische Isolation der Pulmonalvenen (PVI) ist nach wie vor ein entscheidender Endpunkt der interventionellen Behandlung von Vorhofflimmern (AF). Daher sind einige alternative „single-shot“ Kathetertechnologien wie der „Pulmonary Vein Ablation Catheter“ (PVAC®, Medtronic Inc., Minneapolis, MN, USA) entwickelt worden. Dieser Multielektrodenkatheter wird über einen Draht eingeführt und gibt eine phasenverschobene bipolare wie unipolare relativ niedrige Radiofrequenzenergie (RF) ab. Sowohl die Untersuchungsdauer als auch die Durchleuchtungszeit sind für dieses System kürzer verglichen mit der gekühlten RF-Energie. Dies kann durch den Vorteil des gleichzeitigen Mappings und Abladierens bedingt sein, wobei die Signale während der Impulsabgabe artefaktbedingt nicht beurteilbar sind. Auch die Effektivität des PVAC-Katheters ist in randomisierten Studien vergleichbar mit anderen Technologien. Komplikationen treten bei PVAC-Therapie etwa gleich häufig auf wie bei gekühlter RF-Ablation und sind bei Kryoballonablation sogar geringfügig höher. Dennoch sollte dem Auftreten von Thrombembolien und Pulmonalvenenstenosen sowie einer effektiven Antikoagulation besonderes Augenmerk bei PVAC-PVIs gewidmet werden. Das neue Design des PVAC Gold® Katheters wird möglicherweise die Sicherheit verbessern, indem das Thrombembolierisiko durch die fehlende Interaktion der Elektroden 1 und 10 und durch einen besseren Gewebekontakt durch eine 20° Vorwärtsneigung der Katheterspirale verringert wird. Diesbezüglich liegen bislang allerdings noch keine klinischen Daten vor. Zusammenfassend stellt das PVAC-System eine vielversprechende Alternative zur PVI dar. Prospektive Studien mit dem neuen Katheterdesign sind erforderlich, um den zukünftigen Stellenwert des Verfahrens beurteilen zu können.
- Open Access
- 1 January 2013
- Published by Springer Nature in EJNMMI Research
- Vol. 3 (1) , 81
Pulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation
Circumferential pulmonary vein isolation (PVI) is the cornerstone of the current state-of-the-art management of atrial fibrillation (AF). However, the precise mechanisms behind AF relapses post PVI are still unknown. Since the activity of the autonomous nervous system is crucial in triggering paroxysmal AF, we hypothesized that PVI is associated with changes of cardiac sympathetic activity.
- 1 January 2013
- Published by Springer Nature in EJNMMI Research
- Vol. 3 (1) , 81
Open AccessPulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation
Circumferential pulmonary vein isolation (PVI) is the cornerstone of the current state-of-the-art management of atrial fibrillation (AF). However, the precise mechanisms behind AF relapses post PVI are still unknown. Since the activity of the autonomous nervous system is crucial in triggering paroxysmal AF, we hypothesized that PVI is associated with changes of cardiac sympathetic activity.
- 29 May 2009
- Published by Elsevier in International Journal of Cardiology
- Vol. 134 (3) , 412-414
Novel surface ECG criteria for differentiation between left- and right-sided manifest inferoseptal accessory pathways
- 29 May 2009
- Published by Elsevier in International Journal of Cardiology
- Vol. 134 (3) , 412-414
Novel surface ECG criteria for differentiation between left- and right-sided manifest inferoseptal accessory pathways
- 1 January 2008
- Published by Springer Nature
- p. 191-198
Klinik und Therapie von Herzrhythmusstörungen
- 16 February 2005
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 16 (2) , 233-234
A NavX™ Guided Cryoablation of an Accessory Pathway in a Large Coronary Sinus Diverticulum
J Cardiovasc Electrophysiol, Vol. 16, pp. 1-2, February 2005.
- 16 February 2005
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 16 (2) , 233-234
A NavX™ Guided Cryoablation of an Accessory Pathway in a Large Coronary Sinus Diverticulum
J Cardiovasc Electrophysiol, Vol. 16, pp. 1-2, February 2005.